Member Info for donotpanic

More chances of this being approved... Otherwise every one loses... FCA were there to show they doing their bit... now Judge will decide and offer will be accept ... my opinion only though

The latest update will be cheered by shareholders after the company announced last month it was not able to agree a contract extension with the UK Department of Health and Social Care for its exsig Covid-19 direct kits. Approximately 50% of the company’s full year revenue last year came from sales to the DHSC. BIT CONFUSING when we just had this RNS on 17th May 2021

https://uk.investing.com/news/stock-market-news/novacyts-snpsig-test-for-variants-of-concern-included-in-nhs-england-framework-2374629

Exactly people read one RNS and forget what NCYT got in store...

When we had results RNS this dropped to around same price... with in a week this i think went over 500.. SO BUY while cheap

ALL it says NCYT have taken legal action against DHSC ... rest were aware of back above 400

If we say this is fair price today after RNS... so ALL things we have in pipeline and if successful ... THIS IS BOTTOM... ONLY RISE from here... if legal action won this will be back to 8-9

People remember we had other RNS to so do not forget what is in pipeline... think wider.

Nothing has changed... this RNS gave MMS to mug people and hit stop losses...

Reason we dropped from around 6-7 was due to DHSC ... THIS WILL BOUNCE BACK OVER 400

Novacyt delivered revenue for Q1 2021 of €83.0 million (£72.6 million). Approximately 50% of Q1 revenue was driven by sales to the DHSC, predominately PROmate™. The remaining c.50% of Q1 revenue was driven by continued growth of international sales and expansion of the Company's private sector testing operations.



Given the ever-changing nature of the COVID-19 pandemic and diagnostic testing demands, the Company continues to have limited visibility over future sales. Whilst the Directors are confident new contract wins will continue as Novacyt expands international sales and into private sector testing, they believe revenue and profit for 2021 may be lower than current market expectations due to the absence of the DHSC contract extension.



Novacyt expects PROmate™ to continue to be rolled out in hospitals, private sector settings and international markets for the foreseeable future, although the Company believes that Q1 PROmate™ sales may be sufficient to support the NHS current roll out plans for the remainder of 2021.



The Company is encouraged by demand for its mobile processing laboratories and SNPsig® portfolio, both launched in Q1 2021, for private sector testing and detection of COVID-19 variants, respectively. New COVID-19 lateral flow products are also under development, to expand the Company's ability to meet evolving COVID-19 testing demands.

I am in as we all ready aware about DHSC from last RNS...

I am in as we all ready aware about DHSC from last RNS...

Morning ALL.. I think break through will happen with this... break 0.10 and hopefully steady RISE...

Have this closed BLUE again? false close as tomorrow this will start going RED... but who knows... every day this close at 0.10 when buy price is 0.925

I am waiting either this goes down quite a bit to top up or once SP starts moving up steadily... my average is slightly Higher then todays buy price.. so not worth doing any thing yet

Sue joining the team... wait lot more to come here...

We ALL ready know the test results ... just waiting game... soon this price will be HISTORY ... 200 PLUS

May be few directors buys come in

Every one have different opinions... but looks positive to me.. How much though for Greenland we get.. plus do we get shares in other company...